



Republic of the Philippines
Department of Health

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

COBAC RESOLUTION NO. 2018-219-A
27 July 2018

**RECOMMENDING APPROVAL OF THE AWARD OF CONTRACT FOR ITEM NO. 2 FOR THE
PROCUREMENT OF CYCLOPHOSPHAMIDE**
IB NO. 2018-164

WHEREAS, Open Competitive Bidding for the Procurement of Bleomycin-Rebid was conducted in accordance with Republic Act (RA) 9184 and its 2016 Implementing Rules and Regulations (IRR) through the General Appropriations Act of 2018 with a Two Million Eight Hundred Twenty One Thousand Seven Hundred Thirty Four Philippine Pesos (PhP2,821,734.00);

Item No.	Description	Qty.	Unit	Total ABC (PhP)
1	Cyclophosphamide 200mg	1,960	Vial	333,200.00
2	Cyclophosphamide 500mg	10,550	Vial	2,488,534.00
TOTAL				2,821,734.00

WHEREAS, on 09 February 2018, a Pre-procurement Conference took place as scheduled at 9:00 A.M at the COBAC Conference Room, Department of Health (DOH), to determine the readiness of the procurement at hand;

WHEREAS, on 12 February 2018, the Central Office Bids and Awards Committee (COBAC)-A issued a memorandum to the End-User, Disease Prevention and Control Bureau- Lifestyle Related Diseases Division (DPCB-LRDD), requesting confirmation on the comments/suggestion made during the Pre-procurement Conference;

WHEREAS, on 13 February 2018, a response from DPCB-LRDD was received and informing that the revised PRs were already forwarded to Pharmaceutical Division (PD) for clearance;

WHEREAS, on 20 February 2018, a revised PRs was received and reflecting the changes on the ABC;

WHEREAS, on 22 and 28 of February 2018, the COBAC-A issued memoranda to DPCB- LRDD following-up the submission of Allocation List;

WHEREAS, on 28 February 2018, Allocation List was received;

WHEREAS, on 05 March 2018, the Invitation to Bid was published and posted in the PhilGEPS Website and other conspicuous places within the premises of the DOH. The advertisement of the IB in a newspaper of general nationwide circulation provided in Section 21.2.1 (c) of the 2016 IRR of RA 9184 shall not be required for contracts to be bid with an approved budget of PhP10M and below for the procurement of goods;

WHEREAS, the Technical Working Group (TWG) was created through the issuance of Department Personnel Order (DPO) COBAC No. 2018-113 dated 06 March 2018;

WHEREAS, on 13 March 2018, a Pre-bidding Conference took place as scheduled at 10:00 A.M. at the COBAC Conference Room, DOH, with two (2) prospective bidders attending, namely:

1. Metro Drug, Inc. (MDI); and
2. Zuellig Pharma Corporation (ZPC).

WHEREAS, on 14 March 2018, the COBAC-A issued a memorandum to DPCB- LRDD, requesting confirmation on the comments/suggestion made during the Pre-bidding Conference;

WHEREAS, on 20 March 2018, the COBAC-A issued a memorandum following-up the submission of the revised PRs;

WHEREAS, a Bid Bulletin No. 1, dated 21 March 2018 was issued to announce the postponement for the Submission and Opening of Bids previously slated on 27 March 2018;

WHEREAS, a Bid Bulletin No. 2, dated 26 March 2018 was issued clarifying the issues and concerns raised during the Pre-bidding Conference and to announce the new schedule of the Submission and Opening of Bids;

WHEREAS, on 03 April 2018, the Submission of Bids took place as re-scheduled at 9:00 A.M. at the COBAC Conference Room, DOH;

WHEREAS, two (2) prospective bidders purchased the bidding documents and submitted their respective proposals, namely:

1. MDI JV with Interpharma Holdings and Management Corporation (IHMC); and
2. Genace Pharma Distributor (GPD).

WHEREAS, Notice of Change of Schedule dated 03 April 2018 was issued to announce the new schedule of the Opening of Bids from 03 April 2018 to 06 April 2018;

WHEREAS, the Opening of Bids took place as re-scheduled on 06 April 2018 at 9:00 A.M. at the COBAC Conference Room, DOH;

WHEREAS, the first envelopes, containing the Eligibility and Technical Documents were individually opened and the presence, completeness and correctness of all the documents were individually verified by the COBAC-A in the presence of the prospective bidders' representative. Upon checking, MDI JV with IHMC and GPD were declared "ELIGIBLE";

WHEREAS, the second envelopes containing the Financial Proposals were opened and the presence, completeness and correctness of the documents were verified by the COBAC-A. Upon examination, the two (2) "ELIGIBLE" bidders were rated "PASSED", and subsequently their respective proposals were read out publicly and posted in the Abstract of Bids, to wit:

				1	2	
Name of Company				MDI JV WITH IHMC	GPD	
Bid Security				BSD	BSD	
Amount				N/A	N/A	
Validity				N/A	N/A	
REMARKS				ELIGIBLE & PASSED		
Item No.	Item Description	Qty.	Unit	TOTAL ABC (Php)	BID PRICE AS READ (Php)	
1	Cyclophosphamide 200mg	1,960	Vial	333,200.00	NO BID	NO BID
2	Cyclophosphamide 500mg	10,550	Vial	2,488,534.00	1,793,500.00	1,688,000.00
TOTAL				2,821,734.00	1,793,500.00	1,688,000.00

WHEREAS, the COBAC Resolution No. 2018-219 "Declaration of Failure of Bidding for the Item No. 1 – Cyclophosphamide 200mg for the Procurement of Cyclophosphamide under IB No. 2018-164", was approved;

WHEREAS, GPD was declared as the Lowest Bidder (LB) for Item No. 2 subject to further arithmetical review and corrections of the financial bid, to determine the bonafide Lowest Calculated Bidder;

WHEREAS, the bids for the item listed below were found to be substantially complying:

Item No. 2: 10,550 vials of Cyclophosphamide 500mg

Bidder No.	Name of Company	ABC (Php)	Bid as Calculated Amount (Php)	% Variance from ABC
2	GPD	2,488,534.00	1,688,000.00	32.16%
1	MDI JV with IHMC		1,793,500.00	27.92%

WHEREAS, on 10 April 2018, the detailed initial evaluation of the submitted proposals on the legal, technical and financial aspects of the documents of the LCB was undertaken by the designated TWG;

WHEREAS, on 20 April 2018, the TWG found GPD “Non-complying” with the requirement of commercially available in Philippine market for the past two (2) years;

WHEREAS, on 24 April 2018, the cited TWG report was presented to COBAC-A during its 17th Regular Meeting. Upon deliberation, the Committee concurred with the TWG recommendation and declared GPD as “non-compliant”;

WHEREAS, on 25 April 2018, a letter was issued to GPD through facsimile, informing the decision of COBAC-A declaring their bid as “non-compliant”;

WHEREAS, on the same date, the detailed initial evaluation of the submitted proposals on the legal, technical and financial aspects of the documents of the 2nd LCB was undertaken by the designated TWG;

WHEREAS, 15 May 2018, the TWG submitted their initial report of MDI JV with IHMC and requested for clarification on submitted proof of documents wherein the product is currently available in the market;

WHEREAS, on the same date, the cited TWG Report was presented to the COBAC-A during its 19th Regular Meeting;

WHEREAS, on 28 May 2018, the COBAC-A issued a letter to MDI JV with IHMC requesting for clarification on the above-cited findings;

WHEREAS, on 31 May 2018, the COBAC-A received a response from MDI JV with IHMC and it was subsequently forwarded to the designated TWG for further evaluation;

WHEREAS, on 07 June 2018, the TWG submitted their consolidated report and found MDI JV with IHMC “Complying” with the Technical requirements;

WHEREAS, on 13 June 2018, the cited TWG report was presented to COBAC-A during its 23rd Regular Meeting. Upon deliberation, the COBAC-A concurred with the TWG and decided to proceed with the post-qualification evaluation upon receipt of post-qualification documents;

WHEREAS, on the same date, a notification was issued to MDI JV with IHMC, requesting for the submission of post-qualification requirements;

WHEREAS, on 18 June 2018, MDI JV with IHMC submitted its post-qualification requirements and subsequently was forwarded to the TWG, for evaluation;

WHEREAS, on 02 July 2018, the TWG submitted their post-qualification report of MDI JV with IHMC and requested for clarification on the submitted brochure;

WHEREAS, on 03 July 2018, the cited TWG post-qualification report was presented to the COBAC-A during its 25th Regular Meeting;

WHEREAS, on 09 July 2018, the COBAC-A issued a letter to MDI JV with IHMC requesting for clarification on the above-cited findings;

WHEREAS, on 10 July 2018, the COBAC-A received a response from MDI JV with IHMC and it was subsequently forwarded to the designated TWG for further evaluation;

WHEREAS, on 18 July 2018, the TWG-Technical found MDI JV with IHMC “non-responsive” on its post-qualification documents particularly on the brochure and submitted their post-qualification report;

WHEREAS, on 24 July 2018, the TWG Report was presented to COBAC-A during its 28th Regular Meeting and decided to overrule the findings of TWG-Technical, considering that the submitted brochure is consistent with the Certificate of Product Registration (CPR). The COBAC-A recommended the award of contract in favor of MDI JV with IHMC;

WHEREAS, on 27 July 2018, the TWG submitted the Bid Evaluation and Post Qualification Evaluation Reports;

WHEREAS, the COBAC-A reviewed and deliberated the TWG reports, as well as the documents submitted by MDI JV with IHMC. The following are the salient points of discussion:

Item No.	Description	Name of Bidder	Bidder's Rank	ABC (PhP)	Bid Price (PhP)	TWG		COBAC	
						Finding	Recommendation	Finding	Recommendation
2	Cyclophosphamide 500mg	MDI JV with IHMC	2 nd LCB	2,488,534.00	1,793,500.00	The 2 nd LCB passed the post qualification and found to have complied with the legal, technical and financial requirements.	Responsive	<ul style="list-style-type: none">COBAC conforms with the recommendation of the TWG.MDI JV with IHMC is determined to be responsive and post-qualified and recommended for the award of contract for Item No. 2.	2 nd Lowest Calculated Responsive Bid (2 nd LCRB)

WHEREAS, at the time of the signing of this resolution, there is no pending incident, no pending Motion for Reconsideration, no pending Protest and the COBAC-A followed the requirements set forth in R.A. 9184;

NOW THEREFORE, on the basis of the above, the herein members of the COBAC-A HEREBY RESOLVE to recommend the award of contract to **Metro Drug Inc. JV with Interpharma Holdings and Management Corporation** determined as the 2nd LCRB with a Total Contract Price of **One Million Seven Hundred Ninety Three Thousand Five Hundred Philippine Pesos (PhP1,793,500.00)** inclusive of other taxes for the item listed below:

Item No.	Particular	Qty.	Unit	Total Amount (PhP)
2	Cyclophosphamide 500mg	10,550	Vial	1,793,500.00

AUG 08 2018

Signed this ____ day of ____ 2018 at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE - A


LEONITA P. GORGOLON, MHA, MCHM, CEO VI
Regular Member


FERCHITO L. AVELLINO, MD, PHSAE
Regular Member


KENNETH G. RONQUILLO, MD, MPH, CESO III
Vice-Chairperson


MAR WYNN C. BELLO, MD, MPA
Regular Member

NESTOR F. SANTIAGO, JR., MD, MPH, MHS, CESO III
Assistant Secretary of Health
Chairperson

By Authority of the Secretary of Health:


MYRNA C. CABOTAJE, MD, MPH, CESO III
Director IV
Disease Prevention and Control Bureau
SEP 06 2018